Alexandra Balcom

CIK 1862147 · Chief Financial Officer · last filed 2026-06-03

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$10.57M

Companies

2

Total Filings

29

Lifetime Open-Market Net

-$29.56M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NUVL Chief Financial Officer 85,733 $123.25 $10.57M -$29.56M 27 2026-06-03
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Director $15.70 $0 2 2026-06-03

Recent Filings · Page 2 of 3

29 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2025-10-15 NUVL Mixed -$2.82M EDGAR
2025-10-03 NUVL Mixed -$1.53M EDGAR
2025-10-01 NUVL Mixed -$2.16M EDGAR
2025-07-17 NUVL Mixed -$1.31M EDGAR
2025-07-01 NUVL Mixed -$1.22M EDGAR
2025-06-23 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) $0 EDGAR
2025-01-08 NUVL Mixed +14,734 -$320.0K EDGAR
2024-12-18 NUVL Exer (M) +13,700 $66.9K EDGAR
2024-12-03 NUVL Mixed -$679.4K EDGAR
2024-11-04 NUVL Mixed -$613.4K EDGAR
Showing 1120 of 29
Page 2 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.